Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

TUB-030

Antibody-drug conjugate · Cytotoxic, directed at 5T4 (TPBG) · developed by Gilead Sciences

Phase 1/2 Most advanced trial

GILD Developer

1 Registered trials

What is TUB-030?

TUB-030 is an antibody-drug conjugate composed of a humanized IgG1 antibody directed against 5T4 conjugated to exatecan, a DNA topoisomerase I inhibitor. Upon binding 5T4-expressing tumor cells, exatecan is released intracellularly to inhibit DNA replication and induce apoptosis, with a bystander effect on neighboring tumor cells. It is studied in advanced solid tumors including head and neck, small-cell lung, non-small-cell lung, triple-negative breast, and colorectal cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Antibody-drug conjugate
Targets: 5T4 (TPBG), DNA topoisomerase I (TOP1) (secondary target)
Mechanism: Cytotoxic, directed at 5T4 (TPBG)
Pathways: DNA replication inhibition, apoptosis
Therapy area: Oncology
Developer: Gilead Sciences (GILD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06657222	Phase 1/2	Advanced Solid Tumors	Recruiting	GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsCRCHNSCCNSCLCSCLCTNBC - Triple-Negative Breast Cancer

Other drugs acting on TPBG

ALG.APV-527 Phase 1/2

More from Gilead Sciences

Axicabtagene Ciloleucel FDA approved Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind TUB-030

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z